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Three-dimensional quantitative ultrasound spectroscopic imaging of prostate was investigated clinically for the
noninvasive detection and extent characterization of disease in cancer patients and compared to whole-mount,
whole-gland histopathology of radical prostatectomy specimens. Fifteen patients with prostate cancer underwent
a volumetric transrectal ultrasound scan before radical prostatectomy. Conventional-frequency (~5 MHz)
ultrasound images and radiofrequency data were collected from patients. Normalized power spectra were used
as the basis of quantitative ultrasound spectroscopy. Specifically, color-coded parametric maps of 0-MHz
intercept, midband fit, and spectral slope were computed and used to characterize prostate tissue in ultrasound
images. Areas of cancer were identified in whole-mount histopathology specimens, and disease extent was
correlated to that estimated from quantitative ultrasound parametric images. Midband fit and 0-MHz intercept
parameters were found to be best associated with the presence of disease as located on histopathology whole-
mount sections. Obtained results indicated a correlation between disease extent estimated noninvasively based
on midband fit parametric images and that identified histopathologically on prostatectomy specimens, with an r2
value of 0.71 (P b .0001). The 0-MHz intercept parameter demonstrated a lower level of correlation with
histopathology. Spectral slope parametric maps offered no discrimination of disease. Multiple regression analysis
produced a hybrid disease characterization model (r2 = 0.764, P b .05), implying that the midband fit biomarkerReceived 15 September 2014; Revised 13 November 2014; Accepted 17November 2014
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26 QUS Spectroscopy of Prostate Cancer Sadeghi-Naini et al. Translational Oncology Vol. 8, No. 1, 2015had the greatest correlation with the histopathologic extent of disease. This work demonstrates that quantitative
ultrasound spectroscopic imaging can be used for detecting prostate cancer and characterizing disease extent
noninvasively, with corresponding gross three-dimensional histopathologic correlation.
Translational Oncology (2015) 8, 25–34Introduction
Prostate cancer (PCa) is the most common malignancy diagnosed in
men, with a high number of newly diagnosed cases totalling almost
one third of all cancers detected in men annually [1–3]. PCa, most
frequently diagnosed as adenocarcinoma of the prostate, is generally
considered to respond successfully to available treatments if detected
at an early gland-confined stage. Currently, acceptable treatments for
PCa include watchful waiting, radiation therapy, and radical
prostatectomy. Treatment selection is based upon the patient’s
stage of disease, age, and overall health. PCa screening is a very
controversial topic; studies have shown mixed results and a lack of
direct benefits with respect to PCa mortality rates of screened patients
[4]. Similar results appear to be emerging for treated patients with
low-grade, low-risk disease.
Traditional methods of PCa detection include testing of prostate-
specific antigen (PSA) serum levels and digital rectal examination,
with the former being the most widely used. PSA-based testing has
been demonstrated to increase disease detection at an early stage [5].
This method is relatively cost effective, is reproducible, and has added
a more objective criterion for disease identification. However, recent
studies from the Prostate, Lung, Colorectal, and Ovarian Cancer
Screening Trial and the European Randomized Study of Screening
for Prostate Cancer regarding whether PSA screening improves
cancer-specific survival have been conflicting [6,7]. This has
prompted the United States Preventive Services Task Force to issue a
recommendation statement against PSA screening in asymptomatic
men, regardless of race, age, or family history [8]. Criticisms of the PSA
assay as a screening test include its low sensitivity, low specificity, and
appreciable false-positive rates resulting in exposure to side effects from
transrectal biopsies, in addition to leading to an overdiagnosis bias
causing unnecessary treatments and exposure to treatment-related
complications [8–10].
Imaging of the prostate gland for diagnostic screening is feasible
using various modalities such as magnetic resonance imaging (MRI),
computed tomography, and ultrasound [11]. Although they can all be
used to successfully image the prostate, transrectal ultrasound
(TRUS) remains the most commonly used method. Whereas MRI
has very good specificity, it is relatively costly, not widely available,
and poorly tolerated by some patients, and it does not provide real-
time imaging. In contrast, ultrasound-based solutions are frequently
more preferable because they are inexpensive, portable, and typically
better tolerated than MRI and they permit real-time imaging. The
source of contrast in conventional TRUS B-mode images is the
acoustic impedance mismatches between tissue types which result in
different intensities of ultrasound backscattered signal. The hypoechoic
areas demonstrated within these images are typically used in the clinic to
identify putative areas of PCa. In this context, standard B-mode TRUS
has generated relatively poor results in studies of prostatic cancer
detection, and thus, it is generally used as a diagnostic follow-uptechnique rather than an initial screening modality. TRUS is also the
primary imaging modality used in image-guided prostate biopsies.
However, B-mode images of the prostate can vary based on ultrasound
instrumentation used and individual user settings, which makes
objective interpretations and definitive clinically-relevant conclusions
difficult. Prior evidence has demonstrated that quantitative ultrasound
(QUS) imaging of the prostate can increase the detection capability of
biopsies by helping to target areas with a high likelihood of disease
presence [12,13]. Those studies describe early pivotal applications of
spectrum-analysis-based QUS techniques applied to PCa and biopsies
in an effort to overcome the inability of standard ultrasound to detect
PCa reliably.
QUS spectroscopy applies power-spectrum analysis techniques to
process ultrasound backscattered radiofrequency (RF) signals to
determine the bioacoustic properties of the underlying tissue for
characterizing its microstructure. In this method, operator and
instrument-setting variables are eliminated by normalizing ultrasound
signals against a reference in a frequency-dependent manner. This
technique has been demonstrated to be capable of detecting tumor
response to treatment in preclinical models [14,15] and clinical
settings [16–20] and differentiating between various tissue types
[12,13,21,22] including benign versus malignant breast tumors in
animal xenograft models [23,24]. In this context, a theoretical
framework of power-spectrum analysis in tissue characterization was
established by Lizzi et al., in which power-spectrum features were
related to acoustic properties of tissue [25]. In a number of studies
performed by that group, the use of tissue properties such as effective
acoustic scatterer size, effective acoustic scatterer concentration, and
acoustic impedance mismatch has been compared with clinical data
and theoretical models. In those studies, the normalized power
spectrum of the ultrasound backscattered RF signals was shown to
carry rich information regarding tissue microstructure. Such
information has been used for distinguishing different tissue types
in the retina, liver, and prostate [26–28]; for characterizing, with high
sensitivity and specificity, the presence of tumor deposits in lymph
nodes ex vivo [29]; and for determining intravascular plaque
composition and detecting high-risk lesion types, with good
correlation to histopathology [30].
In the study here, we investigated the efficacy of QUS spectroscopy
for the detection and extent characterization of disease noninvasively
in PCa patients. Specifically, three-dimensional QUS spectral
parametric maps were used to determine the areas of the prostate
putatively affected by cancer. The estimated extents of disease were
compared and correlated to those identified from serially-sectioned
whole-mount histopathology of prostatectomy specimens as a gold
standard approach for identifying cancerous areas. Ultrasound images
and RF data were collected from 15 PCa patients before radical
prostatectomy using a TRUS probe operating at ~5 MHz. Ultrasound
images and RF data were collected for each patient volumetrically, in a
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were calculated using a sliding window approach to produce parametric
maps of the 0-MHz intercept, midband fit (MBF), and spectral slope.
Different values of the MBF and 0-MHz intercept parameters were
determined to be associated with the presence of bulk disease as located
on histopathology whole-mount sections separated similarly by 5 mm.
The MBF parameter was found to have the highest level of correlation.
In contrast, parametric maps generated from the spectral slope offered
no discrimination for the cancerous areas. This work demonstrated that
QUS spectroscopic parametric imaging can be applied to detect PCa
noninvasively and to characterize the extent of disease within the
prostate, with demonstrated gross histopathologic correlation. Such an
approach can potentially facilitate PCa diagnosis with an increased
sensitivity and specificity.Material and Methods
Experimental Design and Data Collection
This study was conducted with institutional research ethics
approval from Sunnybrook Health Sciences Centre and was open
to all PCa patients meeting study criteria. Eligible patients included
those confirmed histopathologically with adenocarcinoma of the
prostate gland via a core biopsy procedure, with T2/T3 disease on
histopathologic examination, consented for radical prostatectomy,
not on androgen deprivation therapy, and with no prior chemother-
apy or radiotherapy to the pelvis. In keeping with these, 15 eligible
patients confirmed with localized palpable PCa were recruited for this
study after obtaining written informed consent.
All the ultrasound data in this study were collected following
standardized protocols for data acquisition. The ultrasonographer was
blinded to the biopsy and histopathology results. Patients were scanned
within 2 weeks before their radical prostatectomy in a dorsal lithotomy
position. Volumetric ultrasound images and RF data were acquired in a
set of transverse planes spanning the whole prostate and separated by
5 mm. The position and orientation of the scan planes were controlled
using an in-house rail-based probe mount fixture. Data were collected
using a Sonix RP system (Ultrasonix Medical Corporation, Richmond,
BC, Canada) using a BPC8-4/10 128 element curvilinear array
ultrasound transducer at the tip of a biplane transrectal probe (Vermon
S.A., Tours, France), with a center frequency of ~5 MHz (3.5 to
6.5 MHz, −6 dB bandwidth). Acquired data consisted of ultrasound
B-mode images and RF data collected with a sampling frequency of
40 MHz. The line density applied was 512 with an 85% sector width
permitting for 430 RF lines per frame.
Histopathology Analysis
Patients underwent radical prostatectomy surgery within 1 to 2weeks
after ultrasound data collection. The prostate gland was removed en
bloc, and labeled and orientated properly. Patient prostatectomy
specimens were consequently fixed, sectioned, and mounted on
whole-mount [31] histopathology slides. Fixation was performed in
5% formalin for up to 24 hours. Embedded tissue was sectioned in a
serial manner using steps with 5-mm separation from apex to base at a
90° orientation perpendicular to the urethra, nominally matching the
orientation at which ultrasound scans were performed. Sections were
then cut for staining and microscopy using a Leica SM2500 motorized
sliding microtome (LeicaMicrosystems, Concord, ON, Canada) and
mounted on 2" × 3" glass slides. Staining was performed on each
slide with hematoxylin and eosin. Stained glass slides weresubsequently digitized at 1-μm resolution using a TISSUEscope
4000XT confocal scanner (Huron Technologies, Waterloo, ON,
Canada). The digital images were examined by a pathologist for
detecting and localizing malignancies and abnormal glandular
structures. Specifically, areas of disease were contoured by the
pathologist on images and were subsequently quantified using
ImageJ (NIH, Bethesda, MD). Quantification was performed by
calculating the total area of contoured disease in each prostate section
relative to the area of the entire prostate in that section. Gross disease
content was also determined within the prostate tissue for each
specimen and compared to gross areas of abnormality identified over
the corresponding QUS spectral parametric images, as described in
the following section.Ultrasound Data Analysis
Ultrasound RF data analysis was performed using linear regression
analysis of the normalized power spectrum [12–15]. Ultrasound data
were analyzed for all acquired planes through the scan volume and
over the whole field of view for each plane using a sliding window
approach (described further below). The power spectrum was
calculated using a fast Fourier transform of the raw RF data for
each scan line through the sliding window which was truncated using
a Hamming function, and subsequently averaged. To remove the
effects of system transfer functions, transducer beam forming, and
diffraction artifacts, data were normalized using reference power
spectra obtained from a glass-bead-embedded agar-gel phantom
model [32,33]. Equation (1) describes the process of calculating the
normalized power spectrum:
NPS fð Þ ¼ log
XN
i¼M
F FT Hamming et t; xið Þð Þð Þj j2
XN
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FFT Hamming ep t; xið Þ
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In this equation, NPS ( f ) represents normalized power spectrum
(in dBr) as a function of frequency ( f ); et(t, xi) and ep(t, xi) are RF signals
backscattered by tissue and phantom, respectively, as functions of time (t)
and lateral position (xi) at different RF lines (i = M,M + 1,…, N).
Specifically, the average power spectrum obtained for each sliding
window was normalized separately to a reference curve obtained from
the same region of the phantom, with an equivalent location and size
[Equation (1)]. This was carried out to more accurately account for
the effects of attenuation and beam diffraction across the scan plane.
Linear regression analysis was performed on the normalized power
spectrum of RF data within a −6-dB window (bandwidth of 3.5 to
6.5 MHz) centered at the transducer center frequency ( fc ) to
generate a best-fit line [Equation (2)]. Parameters subsequently
determined included the MBF [Equation (3)], the spectral slope, and
the corresponding 0-MHz intercept [19,25]:
NPS fð Þ ¼ Slope  f þ Intercept ð2Þ
MBF ¼ Slope  f c þ Intercept ð3Þ
Parametric images of these QUS spectral features were generated
by sliding the analysis window over the entire field of view on a pixel-
by-pixel basis. A histogram-based thresholding technique was applied
Table 1. Characteristics of the Patients
Pt. # Age PSA
(ng/ml)
Gleason Score
(out of 10)
Primary Gleason
Component
Secondary Gleason
Component
# Lymph Nodes
Examined
# Lymph Nodes
Involved
Stage of Primary
Disease
1 65 11 9 4 5 5 + 3 0 pT3b
2 74 34.9 8 3 5 4 0 pT2
3 74 7.1 9 4 5 6 1 pT3a
4 68 8 7 3 4 0 0 pT3a
5 68 6.4 9 4 5 4 1 pT3a
6 53 5 7 3 4 5 0 pT3a
7 72 3.3 7 3 4 0 0 pT3a
8 67 7.8 7 4 3 0 0 pT3a
9 69 8.8 7 4 3 0 0 pT2
10 68 6.3 7 3 4 7 0 pT3a
11 63 4.8 7 3 4 2 0 pT2
12 65 5.5 7 4 3 0 0 pT2
13 59 6.2 7 3 4 0 0 pT2
14 67 4.6 7 4 3 6 0 pT2
15 60 45.1 9 4 5 7 0 pT3a
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within the confines of the prostate identified from the corresponding
B-mode images [34,35]. The segmentation threshold was set to
approximately one third (33%) of the mean data value for each
parameter based on previous observations of decreased ultrasound
signal intensity for cancerous areas within the prostate. The relative
area of disease segmented in each image was consequently calculated
with respect to the area of prostate in that image.
Statistical Analysis
Linear regression analysis (PASW Statistics 18, SPSS Inc., Chicago,
IL) was carried out to evaluate potential correlations between the
extent of disease identified based on whole-mount histopathology of
prostatectomy specimens and those estimated noninvasively using
QUS spectral parametric images. A multiple regression analysis was
also performed to identify a model of the best combination of
parameters for predicting the extent of disease as determined based on
histopathology. The input parameters of the model included patient’s
age, PSA level, Gleason score determined from core biopsy specimens,
and the MBF and 0-MHz-intercept-based extent of disease. A P value
of less than .05 was considered in this analysis to identify variables
with statistically significant contributions to the model.
Results
Characteristics of the PCa patients who participated in this study,
along with their disease specification, have been summarized in
Table 1. The patients had an average age of 66 years (SD = 5.7;
range, 53 to 74), with a mean PSA level of 11 ng/ml (SD = 12.1;
range, 3.3 to 45). The clinical T-stage of the cancer initially diagnosed
was either T1c (87%) or T2a (13%). For study enrolment,Figure 1. Representative ultrasound image and QUS spectral parame
of prostate and (B-D) the corresponding QUS spectral parametric imag
bar represents ~1 cm.subsequent examination indicated that all patients had T2 or greater
digitally palpable disease. However, the pathologic T-stage identified
from core biopsy specimens showed more advanced disease with
pT2N0 (40%), pT3aN0 (40%), pT3aN1 (13%), and pT3bN0
(7%). The histopathology analysis indicated Gleason scores of 3 + 4
(40%), 4 + 3 (27%), 3 + 5 (7%), and 4 + 5 (27%) for the patients.
Based on the histopathology of radical prostatectomy specimens, the
areas of prostate involved with cancer were 13% on average.
A representative ultrasound B-mode image of a study patient’s
prostate, along with the corresponding QUS parametric images of the
MBF, 0-MHz intercept, and spectral slope, is presented in Figure 1.
Whereas the MBF and 0-MHz parametric images depicted area of
putative disease (dark regions within the prostate, further described
below) relatively well, the contrast in the parametric map of the
spectral slope was relatively poor. Figure 2 presents a visual
representation of QUS spectroscopic imaging for prostate tissue
characterization using data from a representative patient acquired at
four transverse planes throughout the prostate separated by 5 mm.
Figure 2A shows standard B-mode images obtained without any
additional signal modifications. To extract quantitative information
regarding underlying prostate tissue microstructure to enable
objective disease extent evaluation, spectral parametric images of
the MBF and 0-MHz intercept were generated for the same set of
scan planes from the corresponding ultrasound RF data. The MBF
parametric images obtained are presented in Figure 2B, indicating
relative differences of 9 to 15 dBr between the gross areas of putative
disease and the areas of normal tissue within the prostate. Visual
evaluations demonstrated that the QUS spectral parametric maps
generated had enough sensitivity and specificity to permit generally
the delineation of areas of bulk disease in the prostate by antric maps acquired for a PCa patient. (A) Ultrasound B-mode image
es of theMBF (B), 0-MHz intercept (C), and spectral slope (D). Scale
Figure 2. Ultrasound B-mode images, QUS spectral parametric maps, and the whole-mount histopathology slides corresponding to a
representative PCa patient. Data were acquired at four transverse scan planes throughout the prostate. (A) Ultrasound B-mode images
and (B) the corresponding MBF parametric images acquired at four transverse scan planes throughout the prostate. Scale bar represents
~1 cm. (C) The MBF parametric images with identified areas of putative disease segmented over the images. (D) The whole-mount
histopathology slides obtained from sections of prostatectomy specimen which nominally correspond to the ultrasound scan planes.
Areas outlined in green and orange indicate tumor and hyperplastic areas of abnormality, respectively. Scale bar represents ~1 cm.
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suspicious areas of disease were segmented, as shown in
Figure 2C. Figure 2D illustrates digital images of the whole-
mount histopathology slides obtained from sections of the
corresponding prostatectomy specimen, separated by 5 mm and
roughly matched to the position and orientation of the ultrasound
scan planes presented in Figure 2, A-C. Disease extent was
estimated from the QUS spectral parametric images and
histopathology slides in the form of relative areas of the prostate
affected by cancer (presented in Figure 3). The plots presented in
this figure suggest that the relative areas of disease in the
histopathology images have a relatively good correspondence with
suspicious areas of disease identified noninvasively using the MBF
parametric images but demonstrate a lower level of correlation
with those identified using the parametric images of the 0-MHz
parameter. Specifically, relative areas of 12 ± 4%, 13 ± 5%, and
7 ± 2% were the average extent of disease estimated from whole-
mount histopathology slides, and the parametric images of MBF
and 0-MHz intercept, respectively.Figure 4 demonstrates more comprehensive results of linear
regression analyses performed using the data obtained from all
patients to evaluate the levels of correlation between the extent of
disease identified from the whole-mount histopathology slides and
those predicted noninvasively using QUS spectroscopic imaging, at
different transverse planes. Scatter plots of relative areas of disease
detected based on histopathology versus the MBF and 0-MHZ
intercept parametric imaging are presented in Figure 4, A and B,
respectively, with the best line fitted to the data in addition to the
corresponding 95% confidence interval. Linear regression analysis
resulted in an r2 value of 0.68 (P b .0001), with a 95% confidence
interval ranging between 0.74 and 0.88 for the analysis using the
MBF parametric images. However, the analysis did not result in a
significant correlation for the 0-MHz intercept parametric image
analysis, where an r2 value of 0.06 (P = .20) was obtained, with a
95% confidence interval of −0.03 to 0.45.
Figure 5 presents the relative areas of disease estimated for each
patient on average to further evaluate the efficacy of the technique in a
scenario applicable more practically in clinic. Scatter plots of the
Figure 3. Extent of disease estimated at different scan planes for the representative patient of Figure 2. (A, B) Relative areas of disease identified
from whole-mount histopathology versus those estimated noninvasively using the MBF (A) and 0-MHz intercept (B) parametric images.
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based on histopathology and QUS spectroscopic imaging. Linear
regression analyses were performed to find the lines fitted best to data
and the corresponding 95% confidence intervals, as shown in this
figure. The analyses resulted in correlations with r2 values of 0.71
(P b .0001) and 0.10 (P = .25) and 95% confidence intervals of 0.58
to 0.95 and −0.23 to 0.71 for the MBF and 0-MHz intercept
parametric imaging, respectively.
Relationships between the relative areas of disease estimated based
on QUS spectroscopy and other clinical parameters, including the
Gleason score, PSA level, and age of the patient, were investigated in
the next step. A three-dimensional scatter plot of patient data is
shown in Figure 6, demonstrating the Gleason score versus the
corresponding PSA level and the MBF-based extent of disease for each
patient. The figure implies that the two clinical parameters may not
complement considerably the information provided by the MBF-
based extent of disease. A multiple regression analysis was performed
to better evaluate the contribution levels of the QUS-basedFigure 4. Scatter plots corresponding to the extent of disease e
participating patients. (A, B) Relative areas of disease identified from
using the MBF (A) and 0-MHz intercept (B) parametric images. The lin
within the 95% confidence intervals. The regression analysis resulted
MHZ parametric imaging, respectively.estimations and the clinical parameters to a model predicting the
histopathologic extent of disease. The multiple regression analysis
resulted in a hybrid biomarker [Equation (4)] correlated to the
relative area of disease identified histopathologically with an r2 value
of 0.76 (P b .05):
Hybrid biomarker¼ 0:99MBF‐based extent of diseaseð Þ
þ 0:16 Ageð Þ þ 0:09Gleasonð scoreÞ
þ 0:03 PSA levelð Þ
þð−0:030‐MHz intercept‐based extent
of diseaseÞ  13:09
ð4Þ
Within the model’s input parameters, the MBF-based extent of
disease demonstrated the largest contribution to the prediction model
(P = .003), followed by the age of the patient (P = .28). In addition,
the MBF-based extent of disease was the only parameter thatstimated over different transverse planes of the prostate for all
whole-mount histopathology versus those estimated noninvasively
es were fitted to data via linear regression analyses and presented
in r2 values of 0.68 (P b .0001) and 0.06 (P = .20) for theMBF and 0-
Figure 5. Extent of disease estimated on average for the patients. Plots shows relative areas of disease identified from whole-mount
histopathology versus those estimated noninvasively using the (A) MBF and (B) 0-MHz intercept parametric images. The lines were fitted
to data via linear regression analyses and presented within the 95% confidence intervals. The regression analysis resulted in r2 values of
0.71 (P b .0001) and 0.10 (P = .25) for the MBF and 0-MHZ parametric imaging, respectively.
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biomarker with the relative area of disease identified histopatholog-
ically. Results obtained for the multiple regression analysis have been
summarized in Table 2.
Discussion and Conclusions
The efficacy of QUS spectroscopic imaging for predicating the
histopathologic extent of PCa was investigated using the data
acquired from 15 patients. Volumetric ultrasound images and RF
data were acquired at clinically-relevant low frequencies in a set of
transverse scan planes and processed using QUS spectroscopic
techniques to estimate suspicious areas of disease within the prostate.
Extent of disease estimated based on this type of three-dimensional
QUS analysis of prostate tissue was compared and correlated to that
identified in the corresponding serially-sectioned whole-mount
histopathology of radical prostatectomy specimens.
Obtained results indicated the ability of QUS spectroscopic
imaging to identify regions of the prostate with a high likelihood of
disease presence. In regard to the three spectral parameters
investigated, the MBF and the 0-MHz intercept showed a
considerable degree of sensitivity to changes in the internal structure
of the prostate gland. These parameters can be linked theoretically to
effective acoustic scatterer size, effective acoustic scatterer concentra-
tion, and the acoustic impedance mismatch between the effectiveFigure 6. A three-dimensional scatter plot of the averaged data obta
MBF-based relative area of disease and the PSA level for each patienscatterers and the surrounding medium [25,36]. In contrast, spectral
slope, which is predominantly linked only to the effective acoustic
scatterer size [25,36], was not found to be sensitive to the presence of
cancerous regions in prostate.
The results observed in this study were consistent with those of the
previous landmark research by Feleppa et al. in their examination of
prostate tissue using more limited core needle biopsy specimens
[27,37,38]. Those studies demonstrated that the QUS methods could
detect the presence of disease within prostate tissue as confirmed
histopathologically using biopsy specimens. In the study here,
volumetric ultrasound-based estimates of disease extent were
compared and correlated to volumetric estimates of disease from
whole-mount, whole-gland histopathology. In the research by
Feleppa et al., considerable decreases were identified in the MBF
and the 0-MHz intercept parameters estimated for cancer-affected
prostate samples in comparison with disease-free prostate specimens
[27,37,38]. There, neural network classifiers were also used to predict
the likelihood of malignancy in the prostate compared to disease-free
tissue, where a good performance was reported [39,40]. In addition,
these QUS methods in general have been found applicable for
detecting abnormalities in lymph nodes accurately and with high
sensitivity and specificity using higher-frequency ultrasound [29].
Other investigations by Oelze et al. have also demonstrated that these
methods can discriminate between benign and malignant tissues inined for the patients, demonstrating the Gleason score versus the
t.
Table 2. Results of the Multiple Regression Analysis for Modeling Histopathologic Extent of PCa
Input Variable Coefficient Standard
Error
95% Confidence
Interval
P Value
Age 0.16 0.14 −0.16 0.48 .28
PSA level 0.03 0.07 −0.12 0.18 .68
Gleason score 0.09 0.82 −1.76 1.94 .92
MBF-based extent of disease 0.99 0.25 0.44 1.56 .003 *
0-Mhz-intercept-based extent
of disease
−0.03 0.30 −0.72 0.66 .917
Constant −13.09 10.20 −36.2 9.98 .231
* Statistically highly significant (P b .01).
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of ultrasound-based tissue characterization, a number of studies have
applied this type of spectral analysis for therapy response monitoring,
demonstrating changes in QUS spectral parameters in association
with the histological development of cell death [14–18,41–44]. Such
methods have also been used to track the position of brachytherapy
seeds in prostate [45–47] and to differentiate between vascular lesion
types with good correlation to histopathology [48]. The study
presented here features a volumetric QUS comparison with the three-
dimensional whole-mount histopathology of prostatectomy speci-
mens acquired from PCa patients. The results obtained suggest a
good concordance between the relative areas (extent) of disease
estimated for each patient based on the QUS parametric imaging and
whole-mount histopathology. In addition, the MBF parameter was
found to have the highest level of correlation with presence of
cancerous areas within the prostate. This is consistent with
observations of earlier work conducted by Feleppa et al. [26]. In
the study here, variations were observed, as expected, in the range of
values for each QUS parameter among patients. This was attributed
to several factors that impact ultrasound imaging such as overall size,
density, and internal microstructures of the prostate, which varied
from patient to patient.
Extent of disease estimated using the MBF parametric imaging was
comparable to that identified from histopathology, although the MBF-
based relative areas of disease were observed to be relatively over-
estimated in general. Conversely, spectral 0-MHz intercept parametric
images underestimated the relative areas of disease in most cases and did
not demonstrate a comparable concordance with the results obtained
from the histopathology. The high level of variability observed in the
spectral slope parametric images of prostate tissue obtained for each
patient suggests that the prostate gland is highly heterogeneous in terms
of the size distribution of effective acoustic scatterers. Thismay partly be
related to the influence on the higher order structure of glandular
prostatic tissue by tightly packed carcinoma cells. In addition, factors
such as the presence of widespread intraepithelial neoplasia in many of
the prostate specimens, which also change microstructures of prostate
tissue, may contribute to the variability of results. The findings of our
study are in agreement with previous work with respect to the higher
levels of variability exhibited by the spectral slope parameter and the
inconsistency of that parameter in predicting potential areas of disease
[27]. Histopathologically indicated areas of disease in our study
were correlated relatively well to patient's age, which, as expected,
likely reflects the extent of developed disease, but less correlated to
PSA level. This may be a result of the fact that the majority of the
patients who participated in this research had large clinically palpable
T2/T3 disease.A number of other ultrasound-based tissue characterization
techniques have also been proposed for PCa detection and
localization, such as those implemented in the HistoScanning system
[49–51]. The application of such systems in routine clinical practice is
still under evaluation particularly for smaller lesions [52,53]. The
patients who participated in the study here had, by intent, relatively
large palpable lesions, as the first phase of the study was primarily
conducted for proof of principle. Further evaluation is necessary on
the accuracy of the proposed framework for detecting and
characterizing small and/or nonpalpable lesions. This has been
planned to be investigated in the next phases of the study, where more
patients with various lesion sizes will be recruited.
The extent of disease was estimated in this study using the relative
area of disease, on average, within a number of separated transverse
imaging planes spanning the whole prostate. Three-dimensional
ultrasound data acquisition is, however, required through a
continuous scan sweep or rotation to estimate the volume of disease
within prostate. This has been planned to be investigated as a future
work. Further investigation is also required to evaluate the efficacy of
individual and hybrid QUS biomarkers to predict the tumor grade
and stage of malignancy in PCa patients as important therapeutic
characteristics of the disease.
In the study here, the radical prostatectomy specimens were sectioned
in a serial manner at steps nominally matching the orientation at which
ultrasound scans were performed. The ultrasound-based estimates of
disease extent were compared and correlated to those obtained from
histopathology within the whole volume of the prostate to further
account for the possible slight mismatches between the imaging planes
and histopathology cross sections. Whereas this approach is beneficial to
obtain an approximate correlation between the noninvasive imaging
biomarkers and the standard histopathologic findings, more accurate
coregistration ofQUS images and the histopathology slides is necessary in
case a more precise correspondence is required for specific applications.
Such a multimodal coregistration requires complicated processing blocks
to be incorporated into the diagnostic framework and is currently being
investigated in other studies [54–56].
Applications of other noninvasive imaging modalities for PCa
diagnosis have been investigated in previous studies, including those
based on single photon emission computed tomography, positron
emission tomography, or MRI [11,57–59]. Unlike these imaging
modalities that frequently need external contrast agents, the QUS
techniques used here rely on inherent contrast between normal and
cancerous tissues arising from differences in bioacoustical properties
of these tissues and hence do not need the injection of any exogenous
contrast agents. Ultrasound also has the advantages of low cost, rapid
imaging speed, high resolution, and portability to complement the
aforementioned imaging modalities.
In summary, the QUS-based diagnostic framework investigated in
this study provides further impetus for using such noninvasive
methods for the detection and characterization of disease. Specifically,
the development of the histopathologically proven QUS parameters
associated with the presence of disease in this study can form a basis
for the identification and characterization of PCa and the evaluation
of its response to treatment. In this context, the possibility of
characterizing disease extent in PCa patients noninvasively can
facilitate an early identification of high-/low-risk patients more
accurately [60,61], an objective adjustment of treatment for patients
on an individual basis [62], and the practice of personalized medicine
in targeting PCa.
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